28,157 Sanofi $SNY Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA decreased its position in Sanofi (NASDAQ:SNY) by 5.5% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 483,579 shares of the company’s stock after selling 28,157 shares during the period. Pictet Asset Management Holding SA’s holdings in Sanofi were worth $19,701,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNY. AlphaCentric Advisors LLC boosted its holdings in shares of Sanofi by 5.2% during the third quarter. AlphaCentric Advisors LLC now owns 15,345 shares of the company’s stock worth $633,000 after purchasing an additional 755 shares during the period. Asset One Wealth Management LLC acquired a new position in Sanofi in the 3rd quarter valued at approximately $544,000. International Assets Investment Management LLC acquired a new position in Sanofi in the 3rd quarter valued at approximately $269,000. Genesis Private Wealth LLC increased its stake in Sanofi by 10.2% in the 3rd quarter. Genesis Private Wealth LLC now owns 8,426 shares of the company’s stock valued at $347,000 after buying an additional 782 shares during the period. Finally, Pzena Investment Management LLC lifted its position in Sanofi by 348.2% in the 3rd quarter. Pzena Investment Management LLC now owns 113,396 shares of the company’s stock worth $4,675,000 after buying an additional 88,094 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Wall Street Analyst Weigh In

SNY has been the subject of a number of research reports. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research note on Thursday, October 1st. DZ Bank restated a “buy” rating on shares of Sanofi in a report on Friday, July 31st. HSBC reaffirmed a “buy” rating on shares of Sanofi in a research note on Thursday, September 10th. Sanford C. Bernstein reiterated a “buy” rating on shares of Sanofi in a report on Monday, August 3rd. Finally, Berenberg Bank reissued a “buy” rating on shares of Sanofi in a research report on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and twelve have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $53.00.

Sanofi Trading Up 0.4%

NASDAQ:SNY opened at $48.43 on Thursday. The stock’s 50 day moving average price is $42.52 and its 200 day moving average price is $44.37. Sanofi has a 52 week low of $39.07 and a 52 week high of $52.68. The company has a market capitalization of $117.41 billion, a P/E ratio of 23.98, a P/E/G ratio of 1.32 and a beta of 0.31. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.27 and a current ratio of 1.12.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 30th. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.56 by $0.48. The firm had revenue of $17.25 billion for the quarter, compared to analyst estimates of $14.30 billion. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. The company’s revenue for the quarter was up 16.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.91 earnings per share. On average, research analysts forecast that Sanofi will post 5.07 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.